Survivors of autologous and allogeneic hematopoietic cell transplantation (HCT) for hematologic malignancies face many challenges that may interfere with their quality of life (QOL) [@bib0001], [@bib0002], [@bib0003], [@bib0004], [@bib0005], [@bib0006]. Psychosocial distress, which includes feelings of depression and anxiety, affects 20% to 50% of HCT survivors and persists even years after transplantation [@bib0007], [@bib0008], [@bib0009], [@bib0010], [@bib0011], [@bib0012]. Potential consequences of post-HCT distress and depression include delayed cell engraftment, higher infection rates, post-traumatic stress disorder, decreased medication adherence, and possibly even decreased survival [@bib0013], [@bib0014], [@bib0015], [@bib0016], [@bib0017], [@bib0018], [@bib0019], [@bib0020], [@bib0021], [@bib0022], [@bib0023], [@bib0024]. Impaired physical function is another long-term complication of HCT, with prevalence estimates ranging from 20% to 70% driven in part by comorbidities such as depression or chronic graft-versus-host disease (cGVHD) \[[@bib0007],[@bib0012],[@bib0025]\]. Impaired physical function among HCT survivors may drive financial burden, under- or unemployment, and premature frailty \[[@bib0012],[@bib0026], [@bib0027], [@bib0028]\].

Long-term follow-up (LTFU) clinics integrated within HCT centers offer centralized access to interdisciplinary providers with tools to address elevated distress and impaired physical function. For example, over two thirds of LTFU clinics specifically incorporate access to social workers, psychologists, and physical therapists \[[@bib0029],[@bib0030]\]. However, only about half of the US population lives within a 30-minute driving distance of an HCT center [@bib0031]. HCT survivors who reside further from their transplantation centers have fewer post-HCT appointments than those who live closer \[[@bib0032],[@bib0033]\]. This finding is likely attributable to logistical difficulties associated with attending such appointments, for example, transportation costs as well as the need for patients/caregivers to miss work in order to travel to/from appointments \[[@bib0034],[@bib0035]\]. Although telehealth-based evaluations of HCT recipients are feasible and recommended as a component of LTFU care \[[@bib0035],[@bib0036]\], long-distance survivors may nevertheless be disadvantaged with regard to in-person resources for physical and emotional health such as specialized physical therapy evaluations, thorough evaluations for cGVHD-related fasciitis, or wellness-related group classes with a psychoeducational focus.

Multiple centers have retrospectively investigated whether long driving distances or rural residences affect overall survival after HCT \[[@bib0032],[@bib0034],[@bib0037], [@bib0038], [@bib0039], [@bib0040], [@bib0041], [@bib0042]\]. Although these studies have generally reported no impact of driving distances on *clinical* outcomes, the impact of driving distances on *patient-reported* outcomes (PROs) after HCT is unknown. Even if their post-transplant survival rates are similar to nearer-living peers, long-distance HCT survivors may disproportionately face difficulties with maintaining QOL in the years following HCT. Beyond lessened access and increased hurdles to LTFU resources as previously mentioned, long-distance HCT survivors also have lower incomes compared to their nearer-living peers \[[@bib0032],[@bib0041]\]. Elevated distress and impaired physical function may independently exacerbate these disparities and further impede the ability of long-distance survivors to rebuild their lives after HCT.

As a secondary analysis of a multicenter study, we thus sought to investigate whether long driving distances impact different domains of well-being among long-term HCT survivors as assessed by 2 PRO assessments. Given the potential for long driving distances to impede access to interdisciplinary LTFU resources, we specifically hypothesized that driving distance would be associated with elevated distress and impaired physical function.

MATERIALS AND METHODS {#sec0001}
=====================

Study Enrollment {#sec0002}
----------------

We conducted a secondary analysis of baseline prerandomization data for patients enrolled in the multicenter INSPIRE (INternet and Social media Program with Information and REsources) study investigating a tailored online intervention for adult HCT survivors (clinicaltrials.gov identifier: NCT01602211) [@bib0043]. Survivors were eligible for the INSPIRE study if they resided in the United States or Canada and had received an autologous or allogeneic HCT 2 to 10 years previously as adults (age ≥18 years) for a hematologic malignancy at 1 of 6 US centers: Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance (Seattle, WA), the coordinating center; the University of Nebraska Medical Center (Omaha, NE); Karmanos Cancer Institute (Detroit, MI); Cleveland Clinic (Cleveland, OH); Moffitt Cancer Center (Tampa, FL); or University of Pennsylvania (Philadelphia, PA). Exclusion criteria for the INSPIRE study were (1) relapse or subsequent malignancy in the previous 2 years, (2) serious illness or hospice enrollment precluding participation, (3) insufficient English proficiency to complete PRO assessments, or (4) any issue preventing independent computer or Internet use. However, as noted below, patients were able to complete baseline PRO assessments by mail if they lacked computer or Internet use. The INSPIRE study received institutional review board approval from all 6 participating centers.

Eligible patients were recruited between 2014 and 2017. Once enrolled but before randomization into the INSPIRE study, patients were directed to access a secure website. On this website, they completed a total of 14 electronic PRO assessments in addition to questionnaires about demographic characteristics, comorbidities, survivorship needs, and self-efficacy. Patients were able to complete these assessments over more than 1 sitting. Patients who failed screening for the INSPIRE study because of a lack of computer or Internet access were still asked to complete baseline PRO assessments; these patients were mailed paper copies of all PRO assessments as well as postage-paid return envelopes. Patients who returned these assessments by mail were included in our cross-sectional analysis of baseline data even though they were not subsequently enrolled or randomized in the INSPIRE study.

Study Measures of Interest {#sec0003}
--------------------------

Each HCT center collected ZIP code of primary residence, HCT center, diagnosis prompting HCT, type of HCT (including intensity of conditioning for allogeneic HCT), and method of PRO assessment (online versus mail). Enrolled patients were asked to complete questionnaires detailing their current age; sex; race; partner status, with patients who reported being married or living with their partner defined as having a long-term partner; annual household income in thousands (K) of US dollars, categorized as \<\$20K, \$20K to \$59.9K, \$60K to \$99.9K, or \$100K+ as done previously \[[@bib0010],[@bib0043],[@bib0044]\]; highest level of education; and, for patients who had undergone allogeneic HCT, their current cGVHD severity [@bib0045].

Patients reported cancer-related distress using the 23-item Cancer and Treatment Distress (CTXD) inventory, a PRO measure previously used in HCT survivors [@bib0046], [@bib0047], [@bib0048]. Possible mean CTXD scores range from 0 to 3, where higher CTXD scores indicate higher distress. A CTXD score of \>1.10 among HCT recipients is suggestive of elevated distress [@bib0046]. Patients reported current physical function using the 10-item PRO Measurement Information System 10a (PROMIS) Physical Function inventory, a PRO measure previously validated in patients with cancer [@bib0049]. PROMIS measures incorporating the same or similar items have been used in HCT survivors as well [@bib0050], [@bib0051], [@bib0052]. Raw PROMIS totals were subsequently standardized to the US population with a mean of 50 and standard deviation of 10, thus generating converted T scores (henceforth referred to as PROMIS scores) [@bib0053]. Lower PROMIS scores indicate worse physical function, and a PROMIS score \<40 (1 standard deviation below the population mean) has been used previously in studies of patients with cancer to identify impaired physical function \[[@bib0054],[@bib0055]\].

Statistical Analysis {#sec0004}
--------------------

As in previous studies, driving distances between the centroids of patients' residential ZIP codes and HCT centers were calculated in miles using Google Maps (Google, Mountain View, CA) [@bib0056], [@bib0057], [@bib0058], [@bib0059], [@bib0060], [@bib0061]. When direct driving distances were not calculable because of patient residence on an island, straight-line distances were used as an approximation [@bib0062]. We summarized demographic and clinical characteristics using descriptive statistics, including scatterplots and frequency distributions. We fit univariate logistic regression models to separately predict elevated distress (CTXD score \>1.10) and impaired physical function (PROMIS score \<40). We chose to use these established binary cutoffs for elevated distress and impaired physical function given that minimal important differences in this population have not been established for either the CTXD or PROMIS inventories.

Besides driving distance, other covariates in our regression model included current age, years since HCT, HCT type, PRO assessment method (online versus mail), sex, race, long-term partner status, annual household income category, highest educational level category, and current cGVHD. Current cGVHD scores, which were only asked of allogeneic HCT recipients, were coded as "none" for autologous HCT recipients for regression models to avoid being marked as missing. All analyses were performed using Stata (StataCorp, College Station, TX).

Given the focus of our hypotheses on driving distance, we developed our models using all of the covariates summarized above without performing any stepwise modeling. However, to better delineate the potential of longer driving distances to create logistical hurdles for patients, we also developed secondary post hoc analyses of driving distance operationalized as a dichotomous binary variable: either fewer than 100 miles (\<100 mi) or at least 100 miles (100+ mi). This 100-mile cutoff has been used in previous studies investigating both access to HCT and outcomes after HCT \[[@bib0042],[@bib0057],[@bib0063]\]. While the significance of 100 miles was not explained in these studies, we surmised that patients/caregivers living 100+ miles from their HCT center would likely have to commit their entire days to such appointments given presumed transit times by car exceeding 1.5 hours. While we did not have access to direct data about transit times or appointment scheduling, we adopted this 100-mile dichotomization from previous studies to reflect the fact that driving distance may not correlate linearly with distress or physical function.

RESULTS {#sec0005}
=======

Patient Characteristics {#sec0006}
-----------------------

Of 1775 HCT survivors who were initially screened for the INSPIRE study, 1687 were deemed eligible for baseline assessments as noted in [Figure 1](#fig0001){ref-type="fig"} . Of these patients, 1136 (67%) completed at least 1 PRO assessment and were included in our analysis. CTXD scores were missing for 1 respondent (who received PRO assessments online), while PROMIS scores were missing for 3 respondents (who received PRO assessments by mail). Each HCT center contributed at least 100 patients (range, 110 to 327 patients per center). These 1136 patients resided in 43 US states, 1 US territory (2 patients from Puerto Rico), and 3 Canadian provinces (8 patients altogether).Figure 1Flow diagram of patients included in analysis.Figure 1

Driving distances for all patients ranged from 1 mile to 3895 miles, with a median of 82 miles (interquartile range, 29 to 229 miles). Forty-four percent of patients (n = 506) lived 100+ miles from their HCT centers; this group included 176 patients who lived 500+ miles away and 106 patients who lived 1000+ miles away from their HCT centers (15% and 9% of the total cohort, respectively). Patient characteristics are shown in [Table 1](#tbl0001){ref-type="table"} . As shown, 55% of patients (n = 628) in our analysis had undergone autologous HCT; of the remaining 508 patients who had undergone allogeneic HCT, 384 (76%) had received myeloablative conditioning. A minority of patients (12%, n = 138) completed their PRO assessments by mail after reporting a lack of computer/Internet access at the time of screening. There were no significant differences in clinical or demographic features between the \<100-mile subgroup (55%, n = 630) and the 100+-mile subgroup (45%, n = 506). Median driving distances for these 2 subgroups were 32 miles and 266 miles, respectively.Table 1Characteristics of Enrolled PatientsTable 1Characteristic\<100-Mile Group, No. (%)100+-Mile Group, No. (%)Total, No. (%)*P* Value**[Overall]{.ul}**630(55)506(45)1136(100)**Pre-HCT diagnosis**.21 Leukemia or MDS231(37)190(38)421(37) Lymphoma252(40)217(43)469(41) Myeloma144(23)99(20)243(21) Other3(0)0(0)3(0)**HCT type**.92 Autologous350(56)278(55)628(55) RIC allogeneic70(11)54(11)124(11) MAC allogeneic210(33)174(34)384(34)**Years after HCT***(Missing: n = 1)*.06 ≤ 4.9 years243(39)223(44)466(41) 5+ years386(61)283(56)669(59)**Assessment method**.23 Online560(89)438(87)998(88) Mail70(11)68(13)138(12)**Current age***(Missing: n = 1)*.99 ≤ 40 years62(10)51(10)113(10) 41-64 years352(56)283(56)635(56) ≥ 65 years215(34)172(34)387(34)**Gender**.97 Male333(53)268(53)601(53) Female297(47)238(47)535(47)**Race***(Missing: n = 24)*.18 White580(94)471(96)1051(95) Non-white39(6)22(4)61(5)**Partner status**[\*](#tb1fn1){ref-type="table-fn"}*(Missing: n = 43)*.23 Long-term partner463(77)388(80)851(78) No long-term partner142(23)100(20)242(22)**Annual income***(Missing: n = 98)*.95 ≥ \$100K167(29)143(31)310(30) \$60-99.9K172(30)139(30)311(30) \$20K-\$50.9K176(31)142(31)318(31) ≤ \$19.9K52(9)39(8)91(9)**Highest education***(Missing: n = 44)*.40 Graduate degree133(22)116(24)249(23) Some/all college395(65)321(66)716(65) High school or less77(13)50(10)127(12)**Current cGVHD***(Missing: n = 708)*[†](#tb1fn2){ref-type="table-fn"}.44 None87(38)67(34)154(36) Mild96(42)94(48)190(44) Moderate/severe48(21)36(18)84(20)[^1][^2][^3]

PRO Measures of Distress and Physical Function {#sec0007}
----------------------------------------------

The distribution of CTXD scores (n = 1 missing) revealed a mean score of 0.871 with a standard deviation of 0.612; 32% of patients (n = 359) met criteria for elevated distress. The distribution of PROMIS scores (n = 3 missing) revealed a mean score of 48.5 with a standard deviation of 9.1; 19% of patients (n = 212) met criteria for impaired physical function. A total of 136 patients (12%) met criteria for both elevated distress and impaired physical function. The \<100-mile and 100+-mile subgroups were similar with regard to mean CTXD scores (0.869 versus 0.873; 95% confidence interval, −0.075 to 0.068, 1-sided *P*= .46) and mean PROMIS scores (48.38 versus 48.66; 95% confidence interval, −1.355 to 0.780; *P*= .70). Scatterplots of CTXD and PROMIS scores, each plotted against driving distances in miles, are shown in [Figures 2](#fig0002){ref-type="fig"} A and [2](#fig0002){ref-type="fig"}B, respectively. As shown, scatterplots did not reveal any convincing correlations between CTXD scores and driving distance or between PROMIS scores and driving distance (*r* = −0.015 and *r* = 0.022, respectively).Figure 2Scatterplots of PROs versus driving distance. Driving distances on x-axes are log-transformed for ease of view; however, lines of best fit and correlation coefficients were calculated using original distances in miles. Dashed lines signify the pre-established cutoffs on each PRO assessment (CTXD \>1.10, elevated distress; PROMIS \<40, impaired physical function).Figure 2

The results of our logistic regression modeling for elevated distress and impaired physical function are shown in [Table 2](#tbl0002){ref-type="table"} (driving distance operationalized as a continuous variable) and Supplementary Table S1 (driving distance operationalized as either \<100 miles versus 100+ miles). As shown, driving distance did not emerge as a predictor of elevated distress or impaired physical function in any regression model. When driving distance was operationalized as a continuous variable, the corresponding 95% confidence intervals (rounded to 2 decimal places) were 1.00 to 1.00 in both the regression models for distress as well as for physical function. The differing operationalizations of driving distance did not affect other covariates that were significant predictors of both elevated distress and impaired physical function: current age, assessment by mail, annual household income of below \$60K (and particularly below \$20K), and moderate/severe cGVHD.Table 2Logistic regression with continuous driving distancesTable 2:Elevated distress (CTXD)Impaired physical function (PROMIS)OR95% CIOR95% CI**Driving distance**1.001.00-1.001.001.00-1.00**Current age0.980.97-0.99**[\*](#tb2fn1){ref-type="table-fn"}**1.021.00-1.04**[\*](#tb2fn1){ref-type="table-fn"}**Years after HCT**1.010.94-1.080.980.90-1.07**HCT type***(Reference: autologous)* RIC allogeneic0.940.51-1.751.710.83-2.52 MAC allogeneic0.860.55-1.361.090.61-1.96**Assessment method***(Reference: online)* Mail**2.781.74-4.43**[\*](#tb2fn1){ref-type="table-fn"}**2.661.60-4.42**[\*](#tb2fn1){ref-type="table-fn"}**Gender***(Reference: male)* Female1.270.94-1.72**1.681.16-2.45\*Race***(Reference: white)* Non-white1.220.64-2.320.860.38-1.91**Long-term partner***(Reference: long-term partner)* No long-term partner**0.540.36-0.82**[\*](#tb2fn1){ref-type="table-fn"}0.820.51-1.32**Household income***(Reference: ≥ \$100K annually*) \$60-99.9K**1.851.23-2.80**[\*](#tb2fn1){ref-type="table-fn"}1.370.78-2.40 \$20K-\$50.9K**2.721.76-4.20**[\*](#tb2fn1){ref-type="table-fn"}**2.701.57-4.64**[\*](#tb2fn1){ref-type="table-fn"} ≤ \$19.9K**5.142.69-9.82**[\*](#tb2fn1){ref-type="table-fn"}**5.942.83-12.4**[\*](#tb2fn1){ref-type="table-fn"}**Highest education***(Reference: graduate degree)* Some/all college1.060.72-1.561.110.58-2.15 High school or less1.720.98-3.021.350.70-2.59**Current cGVHD***(Reference: none, including autologous HCT)*[†](#tb2fn2){ref-type="table-fn"} Mild1.360.81-2.291.110.58-2.15 Moderate/severe**7.664.01-14.6**[\*](#tb2fn1){ref-type="table-fn"}**8.004.02-15.9**[\*](#tb2fn1){ref-type="table-fn"}[^4][^5][^6]

DISCUSSION {#sec0008}
==========

In our multicenter retrospective analysis of over 1100 HCT survivors, almost a third of patients reported elevated distress while 19% of patients reported impaired physical function. Surprisingly, we found no impact of increasing driving distance on either of these PRO assessments. This finding contradicts our hypothesis that long driving distances would represent an impediment to well-being among HCT survivors because of fewer appointments and increased hurdles to accessing care. Indeed, when operationalized as a continuous variable, the impact of driving distance in our regression models was entirely negligible (with 95% confidence intervals remaining at unity for both distress and physical function). When operationalized as a dichotomous variable to highlight possibly disproportionate disparities among patients living 100+ miles from their HCT centers, we did not identify even a trend toward impaired well-being mediated by driving distance on either of our 2 separate PRO inventories.

In contrast to driving distance, our study highlights the comparative importance of other variables with regard to impeding post-HCT well-being multidimensionally. Current cGVHD burden and low income were strong predictors of both elevated distress and impaired physical function, both in line with earlier studies of HCT survivors \[[@bib0001],[@bib0005],[@bib0010],[@bib0026],[@bib0050],[@bib0064],[@bib0065]\]. Advancing age was associated with impaired physical function but *lower* distress from a statistical standpoint; however, the near-unity odds ratios suggest that this finding is not clinically meaningful. We were surprised to find that survivors who lacked Internet access (and therefore completed assessments by mail) were over twice as likely to report PRO impairments even after adjusting for age, current cGVHD burden, and other socioeconomic variables. Previous studies have identified age, race, income, and educational level as factors associated with lower Internet usage among cancer survivors \[[@bib0066],[@bib0067]\]. To our knowledge, this is the first study associating a lack of Internet access with worsened PROs among HCT survivors even after adjusting for these related demographic and socioeconomic variables.

Strengths of our study include a large national study sample, high enrollment rate among eligible survivors, and the use of previously validated PRO measures of cancer-related distress and physical function. However, we are limited by the cross-sectional nature of our data and by a lack of information about prior ZIP codes (if any) in which HCT survivors may have resided. We do not have any data about the frequencies of LTFU clinic appointments in our population, which have been previously posited to explain disparities among HCT survivors attributed to driving distances [@bib0032]. Specific outreach practices by individual HCT centers likely varied between centers and uniformly strengthened over time in ways that we are unable to assess. Lastly, with regard to PRO assessment by mail as a surrogate for lack of Internet/computer access, it is possible that HCT survivors may have opted for mail-based assessments due to other reasons. However, cGVHD-related functional impairments limiting usage of a computer were unlikely to be related to assessment methods given that proportions of patients using mail-based assessments were essentially identical among allogeneic HCT recipients regardless of their current cGVHD burden (7% to 8%; data not shown).

**Impacts of Driving Distance on HCT Survivorship** {#sec0009}
---------------------------------------------------

As noted previously, most previous studies have shown no impact of long driving distances or rural residences on *clinical* outcomes after HCT \[[@bib0032],[@bib0034],[@bib0037], [@bib0038], [@bib0039], [@bib0040], [@bib0041], [@bib0042]\]. Our study adds to this literature by investigating driving distance and *patient-reported* outcomes after HCT. We hypothesized that long-distance HCT survivors would have decreased access to care at their LTFU clinics, thereby creating disparities with regard to interdisciplinary resources such as social work, physical therapy, comprehensive cGVHD evaluations, and wellness-related psychoeducational classes. We hypothesized that these difficulties would be particularly exacerbated in patients with driving distances of 100+ miles, where longer travel times might have been disproportionately disruptive and stressful with regard to the structure of their (and their caregivers') normal days.

Our unexpectedly negative results with regard to driving distance and PROs are possibly a reflection of 2 underlying factors: (1) adequate telehealth follow-up or (2) differential loss to follow-up. With regard to the first factor, telehealth follow-up---which can range from phone calls to video visits to biometric data monitoring---is considered a core component of LTFU care for HCT survivors [@bib0035]. More integrative telehealth strategies include digital coaching programs, which have been shown to improve QOL and pain among HCT survivors \[[@bib0068],[@bib0069]\]. It is possible that these types of telehealth approaches bridge any gaps created by long driving distances in HCT survivors, which is a reassuring statement given the rapidly expanding role of telehealth in oncology as a result of the ongoing coronavirus disease 2019 (COVID-19) pandemic. However, we did find a concerning association between mail-based assessments (a surrogate for lack of Internet access) and impairments in both cancer-related distress and physical function. Routine telehealth technologies for patients with cancer often involve the use of online videoconferencing platforms \[[@bib0070],[@bib0071]\]. As such, ensuring that a "digital divide" does not prevent vulnerable patients without Internet access from benefiting from high-quality survivorship care should remain a priority for LTFU clinics as telehealth continues to expand.

Alternatively, it is possible that the subgroup of long-distance survivors who completed PRO assessments for our baseline analysis may have been more motivated to maintain their mental and physical health than their similarly long-distance peers who had already been lost to follow-up (or who declined enrollment in the INSPIRE study). While speculative, the possibility of selection bias is bolstered by a recent registry-based study by the Center for International Blood and Marrow Transplant Research showing that long driving distances are associated with higher rates of becoming lost to follow-up [@bib0063]. Correlative work from previous studies suggests that HCT survivors who drop out of longitudinal studies may have worsened physical health and psychological well-being \[[@bib0072],[@bib0073]\]. Whether less highly functioning long-distance HCT survivors may similarly drop out of longitudinal follow-up even before enrollment in survivorship studies such as ours remains an unknown question in need of future investigation.

In conclusion, our multicenter retrospective analysis of over 1100 HCT survivors demonstrated no relationship between driving distance and PROs measuring distress or physical function. Instead, consistent predictors of impaired well-being across different PRO domains included cGVHD, annual income, and lack of Internet access. With regard to the latter risk factor, LTFU clinics should ensure that increasing telehealth adoption does not exacerbate well-being for patients on the wrong side of the "digital divide." In contrast, driving distances themselves can constitute a small component but certainly not the entirety of how LTFU care is delivered.

Appendix. Supplementary materials {#sec0011}
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[^1]: MDS, myelodysplastic syndrome; RIC, reduced-intensity conditioning; MAC, myeloablative conditioning; K, thousands of US dollars annually.

[^2]: Long-term partner included patients who reported being married or living with their partner. Patients who reported being single, separated, divorced, or widowed were classified as lacking a long-term partner.

[^3]: cGVHD status was only asked of allogeneic HCT recipients. As such, this question was not answered by autologous HCT recipients (*n* = 628). Among allogeneic HCT recipients, 80 responses to this question were missing.

[^4]: Driving distances from HCT centers (in miles) were operationalized as a continuous variable. Model statistics suggested good fits (elevated distress: LR chi-square 149.3, *p* \< 0.000; impaired physical function, LR chi-square 159.0, *p* \< 0.000).

[^5]: Statistically significant (*p* \< 0.05).

[^6]: Current cGVHD scores, which were only asked of allogeneic HCT recipients, were coded as 'None' for autologous HCT recipients for regression models to avoid being marked as missing. Abbreviations: CTXD, Cancer and Treatment Distress; PROMIS, Patient-Reported Outcome Measurement Information System Physical Function; OR, odds ratio; CI, confidence interval; HCT, hematopoietic cell transplantation; RIC, reduced-intensity conditioning; MAC, myeloablative conditioning; K, thousands of US dollars annually; cGVHD = chronic graft-versus-host disease; LR, likelihood ratio.
